RhumbLine Advisers’s KalVista Pharmaceuticals KALV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$615K Buy
54,376
+1,458
+3% +$16.5K ﹤0.01% 2551
2025
Q1
$611K Buy
52,918
+1,762
+3% +$20.3K ﹤0.01% 2444
2024
Q4
$433K Buy
51,156
+877
+2% +$7.43K ﹤0.01% 2764
2024
Q3
$582K Sell
50,279
-2,949
-6% -$34.1K ﹤0.01% 2598
2024
Q2
$627K Buy
53,228
+5,908
+12% +$69.6K ﹤0.01% 2511
2024
Q1
$561K Buy
47,320
+1,959
+4% +$23.2K ﹤0.01% 2602
2023
Q4
$556K Buy
45,361
+3,466
+8% +$42.5K ﹤0.01% 2604
2023
Q3
$403K Buy
41,895
+164
+0.4% +$1.58K ﹤0.01% 2736
2023
Q2
$376K Buy
41,731
+2,909
+7% +$26.2K ﹤0.01% 2876
2023
Q1
$305K Buy
38,822
+1,237
+3% +$9.72K ﹤0.01% 2607
2022
Q4
$254K Buy
37,585
+72
+0.2% +$487 ﹤0.01% 2726
2022
Q3
$544K Buy
37,513
+2,844
+8% +$41.2K ﹤0.01% 2462
2022
Q2
$341K Buy
34,669
+12,519
+57% +$123K ﹤0.01% 2690
2022
Q1
$326K Buy
22,150
+3,100
+16% +$45.6K ﹤0.01% 2613
2021
Q4
$252K Sell
19,050
-11
-0.1% -$146 ﹤0.01% 2763
2021
Q3
$333K Buy
19,061
+897
+5% +$15.7K ﹤0.01% 2725
2021
Q2
$435K Sell
18,164
-5,013
-22% -$120K ﹤0.01% 2630
2021
Q1
$595K Buy
23,177
+4,188
+22% +$108K ﹤0.01% 2407
2020
Q4
$361K Buy
18,989
+3,236
+21% +$61.5K ﹤0.01% 2587
2020
Q3
$198K Sell
15,753
-1,897
-11% -$23.8K ﹤0.01% 2692
2020
Q2
$214K Buy
17,650
+6,923
+65% +$83.9K ﹤0.01% 2736
2020
Q1
$82K Sell
10,727
-150
-1% -$1.15K ﹤0.01% 2811
2019
Q4
$194K Buy
10,877
+238
+2% +$4.25K ﹤0.01% 2757
2019
Q3
$123K Sell
10,639
-80
-0.7% -$925 ﹤0.01% 2853
2019
Q2
$237K Buy
+10,719
New +$237K ﹤0.01% 2719
2016
Q2
Sell
-973
Closed -$9K 3005
2016
Q1
$9K Hold
973
﹤0.01% 2988
2015
Q4
$49K Buy
+973
New +$49K ﹤0.01% 3003